MedTrace Logo

Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

NCT01066611 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2011-05-05

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effect of CAL-263 in subjects with allergic rhinitis.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

CAL-263

CAL-263 10 mg or placebo once daily for 7 days

DRUG

Placebo

CAL-263 10 mg or placebo once daily for 7 days

Sponsors & Collaborators

Principal Investigators

  • Friedrich Horak, MD · Vienna Challenge Chamber

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01066611 on ClinicalTrials.gov